# Kimberly Blackwell

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kimberly-blackwell/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,016 |
| Field | HER2/EGFR in Cancer Research |
| h-index | 60 |
| i10-index | 117 |
| Last Known Institution | Duke University |
| OpenAlex ID | https://openalex.org/A5112904379 |
| Works | 259 |

## Researcher papers

- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pertuzumab-trastuzumab-and-docetaxel-for-her2-positive-metastatic-breast-cancer/)
- [Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas](https://scholariq.org/papers/phase-i-safety-pharmacokinetics-and-clinical-activity-study-of-lapatinib/)

## Researcher topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Duke University](https://scholariq.org/institutions/duke-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.